MCAD Antibody (H-7): sc-365108

MCAD Antibody (H-7) is a mouse monoclonal IgM antibody that detects medium-chain acyl-CoA dehydrogenase (MCAD) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-MCAD antibody (H-7) plays a crucial role in identifying the presence and levels of MCAD, a key enzyme involved in the mitochondrial fatty acid β-oxidation pathway, which is essential for the metabolism of medium-chain fatty acids ranging from C4 to C12. The proper functioning of MCAD is vital, as deficiencies can lead to severe metabolic disorders, including fasting hypoglycemia and hepatic dysfunction, particularly in infants. MCAD (H-7) monoclonal antibody recognizes a homotetramer composed of 421 amino acids, featuring mitochondrial protein transit peptides that facilitate localization to the mitochondrion, where MCAD catalyzes the initial reaction in the β-oxidation process. Notably, MCAD exhibits a high degree of sequence identity with its porcine counterpart, underscoring evolutionary conservation and importance in energy metabolism. Anti-MCAD antibody (H-7) enables researchers to gain insights into the metabolic pathways involving medium-chain fatty acids and their implications in various physiological and pathological conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MCAD Antibody (H-7) References:

1. Expression of wild-type and mutant medium-chain acyl-CoA dehydrogenase (MCAD) cDNA in eucaryotic cells.  |  Jensen, TG., et al. 1992. Biochim Biophys Acta. 1180: 65-72. PMID: 1382617
2. Functional studies of 18 heterologously expressed medium-chain acyl-CoA dehydrogenase (MCAD) variants.  |  Koster, KL., et al. 2014. J Inherit Metab Dis. 37: 917-28. PMID: 24966162
3. Phosphorylation of MCAD selectively rescues PINK1 deficiencies in behavior and metabolism.  |  Course, MM., et al. 2018. Mol Biol Cell. 29: 1219-1227. PMID: 29563254
4. MCAD deficiency caused by compound heterozygous pathogenic variants in ACADM.  |  Nohara, F., et al. 2022. Hum Genome Var. 9: 2. PMID: 35034956
5. MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH.  |  Wang, Y., et al. 2022. J Mol Endocrinol. 69: 415-430. PMID: 35900373
6. Chaetomorpha linum polysaccharides alleviate NAFLD in mice by enhancing the PPARα/CPT-1/MCAD signaling.  |  Chu, X., et al. 2022. Lipids Health Dis. 21: 140. PMID: 36529726
7. Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease.  |  Tang, C., et al. 2023. Drug Des Devel Ther. 17: 1503-1514. PMID: 37223723
8. Assessing the quality and value of metabolic chart data for capturing core outcomes for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.  |  Iverson, R., et al. 2024. BMC Pediatr. 24: 37. PMID: 38216926
9. CACS, CCTA and mCAD-LT score in the pre-transplant assessment of coronary artery disease and the prediction of post-transplant cardiovascular events.  |  Pagano, G., et al. 2024. Liver Int. 44: 1912-1923. PMID: 38591767

The preferred MCAD antibody is MCAD Antibody (E-8): sc-271931.